マーケットレポート詳細
眼科薬の世界市場：2031年予測
Ophthalmic Drugs Market (Therapeutic Class: Anti-VEGF Agents, Anti-glaucoma Drugs, Anti-inflammatory Drugs, Anti-infective Drugs, Anti-allergy Drugs, and Others) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2023-2031
- 出版元：Transparency Market Research
出版元について - 発行年：2023年5月
- 定価 ：Single User License(1名様ライセンス)US$5,795(米国ドル)/ Multi User License $8,795 / Corporate User License $11,795
- ご予算に応じた各種ご提案も承ります。詳細はお問い合わせください。
- ご請求は円換算（お見積り日TTSレート）となります。
- 納品形態：PDF by Email
- 当調査レポートは英文292ページになります。
- 商品コード：TMR020
お問い合わせ、お見積りのリクエストは下のボタンをクリックしてご入力ください。
【レポート紹介】
眼科薬の世界市場規模は2022年で314億ドル、2031年に528億ドル、市場の平均年成長率は6.2%増で推移するとレポートは予測しています。
当レポートでは、眼科薬の市場予測-2031年、各種セグメント別市場分析(治療クラス別、適応症別、国地域別、等)、パイプライン、市場シェア、主要企業プロフィールなどの情報を盛り込み、概略以下の構成でお届けいたします。
【レポート構成概要】
■眼科薬の世界市場予測2017-2031年
・市場規模(US$)
■治療クラス別、市場-2031年
抗VEGF薬
緑内障薬
・α作動薬
・β遮断薬
・プロスタグランジンアナログ
・併用薬
・その他
抗炎症薬
・ステロイド
・非ステロイド性抗炎症薬
抗感染症薬
・抗菌薬
・抗真菌薬
・その他
抗アレルギー剤
その他
※(市場規模US$)
■適応症別、市場-2031年
ドライアイ
緑内障
感染症・炎症
網膜疾患
・ウェットAMD
・ドライAMD
・糖尿病網膜症
・その他
アレルギー
ぶどう膜炎
その他
※(市場規模US$)
■投与経路別、市場-2031年
局所
眼局所（硝子体内）
その他
※(市場規模US$)
■製品タイプ別、市場-2031年
一般用医薬品(OTC)
処方箋
※(市場規模US$)
■剤形別、市場-2031年
点眼薬
点眼液、懸濁液
カプセル、錠剤
ジェル
軟膏
その他
※(市場規模US$)
■販売チャネル別、市場-2031年
病院薬局
小売薬局
オンライン薬局
※(市場規模US$)
■主要国地域別市場-2031年
北米
・米国、カナダ
欧州
・英国、ドイツ、フランス、スペイン、イタリア
・その他欧州
アジア太平洋
・日本、中国、インド
・ニュージーランド/オーストラリア
・その他アジア太平洋
中東アフリカ
・GCC諸国、南アフリカ
・その他中東アフリカ
南米
・ブラジル、メキシコ
・その他南米
※地域別に各種セグメント別の細分化データ掲載、詳細は目次参照
■市場分析
市場ダイナミクス
有病率/発生率
パイプライン
市場シェア
競合状況
■眼科薬の主要企業プロフィール動向
AbbVie, Inc.
Alcon Vision LLC
Bausch Health Companies, Inc.
Bayer AG
Coherus BioSciences
F. Hoffmann-La Roche Ltd.
Novartis Pharmaceuticals Corporation
Pfizer, Inc.
Regeneron Pharmaceuticals, Inc.
参天製薬株式会社
Sun Pharmaceutical Industries Ltd.
Teva Pharmaceutical Industries Ltd.
（全292頁）
【レポート詳細目次、データ項目一覧は当ページ下を参照ください】
Table of Contents (英文詳細目次）
1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Ophthalmic Drugs Market
4. Market Overview
4.1. Introduction
4.1.1. Segment Definition
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Ophthalmic Drugs Market Volume Forecast, by Dosage Form, 2017-2031
5. Key Insights
5.1. Disease Prevalence & Incidence rate globally with key countries
5.2. Pipeline Analysis
5.3. Key Industry Events
5.4. Covid-19 Pandemic Impact on the Industry
6. Global Ophthalmic Drugs Market Analysis and Forecast, by Therapeutic Class
6.1. Introduction & Definition
6.2. Key Findings / Developments
6.3. Market Value Forecast, by Therapeutic Class, 2017-2031
6.3.1. Anti-VEGF Agents
6.3.2. Anti-glaucoma Drugs
6.3.2.1. Alpha Agonist
6.3.2.2. Beta Blockers
6.3.2.3. Prostaglandin Analogs
6.3.2.4. Combined Medication
6.3.2.5. Others
6.3.3. Anti-inflammatory Drugs
6.3.3.1. Steroids
6.3.3.2. NSAIDs
6.3.4. Anti-infective Drugs
6.3.4.1. Anti-bacterial Drugs
6.3.4.2. Anti-fungal Drugs
6.3.4.3. Others
6.3.5. Anti-allergy Drugs
6.3.6. Others
6.4. Market Attractiveness Analysis, by Therapeutic Class
7. Global Ophthalmic Drugs Market Analysis and Forecast, by Indication
7.1. Introduction & Definition
7.2. Key Findings / Developments
7.3. Market Value Forecast, by Indication, 2017-2031
7.3.1. Dry Eye
7.3.2. Glaucoma
7.3.3. Infection/Inflammation
7.3.4. Retinal Disorders
7.3.4.1. Wet AMD
7.3.4.2. Dry AMD
7.3.4.3. Diabetic Retinopathy
7.3.4.4. Others
7.3.5. Allergy
7.3.6. Uveitis
7.3.7. Others
7.4. Market Attractiveness Analysis, by Indication
8. Global Ophthalmic Drugs Market Analysis and Forecast, by Route of Administration
8.1. Introduction & Definition
8.2. Key Findings / Developments
8.3. Market Value Forecast, by Route of Administration, 2017-2031
8.3.1. Topical
8.3.2. Local Ocular (intravitreal)
8.3.3. Others
8.4. Market Attractiveness Analysis, by Route of Administration
9. Global Ophthalmic Drugs Market Analysis and Forecast, by Product Type
9.1. Introduction & Definition
9.2. Key Findings / Developments
9.3. Market Value Forecast, by Product Type, 2017-2031
9.3.1. Prescription
9.3.2. OTC
9.4. Market Attractiveness Analysis, by Product Type
10. Global Ophthalmic Drugs Market Analysis and Forecast, by Dosage Form
10.1. Introduction & Definition
10.2. Key Findings / Developments
10.3. Market Value Forecast, by Dosage Form, 2017-2031
10.3.1. Eye Drops
10.3.2. Eye Solutions & Suspensions
10.3.3. Capsules & Tablets
10.3.4. Gels
10.3.5. Ointments
10.3.6. Others
10.4. Market Attractiveness Analysis, by Dosage Form
11. Global Ophthalmic Drugs Market Analysis and Forecast, by Distribution Channel
11.1. Introduction & Definition
11.2. Key Findings / Developments
11.3. Market Value Forecast, by Distribution Channel, 2017-2031
11.3.1. Hospital Pharmacies
11.3.2. Retail Pharmacies
11.3.3. Online Pharmacies
11.4. Market Attractiveness Analysis, by Distribution Channel
12. Global Ophthalmic Drugs Market Analysis and Forecast, by Region
12.1. Key Findings
12.2. Market Value Forecast, by Region
12.2.1. North America
12.2.2. Europe
12.2.3. Asia Pacific
12.2.4. Latin America
12.2.5. Middle East & Africa
12.3. Market Attractiveness Analysis, by Region
13. North America Ophthalmic Drugs Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.2. Market Value Forecast, by Therapeutic Class, 2017-2031
13.2.1. Anti-VEGF Agents
13.2.2. Anti-glaucoma Drugs
13.2.2.1. Alpha Agonist
13.2.2.2. Beta Blockers
13.2.2.3. Prostaglandin Analogs
13.2.2.4. Combined Medication
13.2.2.5. Others
13.2.3. Anti-inflammatory Drugs
13.2.3.1. Steroids
13.2.3.2. NSAIDs
13.2.4. Anti-infective Drugs
13.2.4.1. Anti-bacterial Drugs
13.2.4.2. Anti-fungal Drugs
13.2.4.3. Others
13.2.5. Anti-allergy Drugs
13.2.6. Others
13.3. Market Value Forecast, by Indication, 2017-2031
13.3.1. Dry Eye
13.3.2. Glaucoma
13.3.3. Infection/Inflammation
13.3.4. Retinal Disorders
13.3.4.1. Wet AMD
13.3.4.2. Dry AMD
13.3.4.3. Diabetic Retinopathy
13.3.4.4. Others
13.3.5. Allergy
13.3.6. Uveitis
13.3.7. Others
13.4. Market Value Forecast, by Route of Administration, 2017-2031
13.4.1. Topical
13.4.2. Local Ocular (intravitreal)
13.4.3. Others
13.5. Market Value Forecast, by Product Type, 2017-2031
13.5.1. Prescription
13.5.2. OTC
13.6. Market Value Forecast, by Dosage Form, 2017-2031
13.6.1. Eye Drops
13.6.2. Eye Solutions & Suspensions
13.6.3. Capsules & Tablets
13.6.4. Gels
13.6.5. Ointments
13.6.6. Others
13.7. Market Value Forecast, by Distribution Channel, 2017-2031
13.7.1. Hospital Pharmacies
13.7.2. Retail Pharmacies
13.7.3. Online Pharmacies
13.8. Market Value Forecast, by Country, 2017-2031
13.8.1. U.S.
13.8.2. Canada
13.9. Market Attractiveness Analysis
13.9.1. By Therapeutic Class
13.9.2. By Indication
13.9.3. By Route of Administration
13.9.4. By Product Type
13.9.5. By Dosage Form
13.9.6. By Distribution Channel
13.9.7. By Country
14. Europe Ophthalmic Drugs Market Analysis and Forecast
14.1. Introduction
14.1.1. Key Findings
14.2. Market Value Forecast, by Therapeutic Class, 2017-2031
14.2.1. Anti-VEGF Agents
14.2.2. Anti-glaucoma Drugs
14.2.2.1. Alpha Agonist
14.2.2.2. Beta Blockers
14.2.2.3. Prostaglandin Analogs
14.2.2.4. Combined Medication
14.2.2.5. Others
14.2.3. Anti-inflammatory Drugs
14.2.3.1. Steroids
14.2.3.2. NSAIDs
14.2.4. Anti-infective Drugs
14.2.4.1. Anti-bacterial Drugs
14.2.4.2. Anti-fungal Drugs
14.2.4.3. Others
14.2.5. Anti-allergy Drugs
14.2.6. Others
14.3. Market Value Forecast, by Indication, 2017-2031
14.3.1. Dry Eye
14.3.2. Glaucoma
14.3.3. Infection/Inflammation
14.3.4. Retinal Disorders
14.3.4.1. Wet AMD
14.3.4.2. Dry AMD
14.3.4.3. Diabetic Retinopathy
14.3.4.4. Others
14.3.5. Allergy
14.3.6. Uveitis
14.3.7. Others
14.4. Market Value Forecast, by Route of Administration, 2017-2031
14.4.1. Topical
14.4.2. Local Ocular (intravitreal)
14.4.3. Others
14.5. Market Value Forecast, by Product Type, 2017-2031
14.5.1. Prescription
14.5.2. OTC
14.6. Market Value Forecast, by Dosage Form, 2017-2031
14.6.1. Eye Drops
14.6.2. Eye Solutions & Suspensions
14.6.3. Capsules & Tablets
14.6.4. Gels
14.6.5. Ointments
14.6.6. Others
14.7. Market Value Forecast, by Distribution Channel, 2017-2031
14.7.1. Hospital Pharmacies
14.7.2. Retail Pharmacies
14.7.3. Online Pharmacies
14.8. Market Value Forecast, by Country/Sub-region, 2017-2031
14.8.1. Germany
14.8.2. U.K.
14.8.3. France
14.8.4. Spain
14.8.5. Italy
14.8.6. Rest of Europe
14.9. Market Attractiveness Analysis
14.9.1. By Therapeutic Class
14.9.2. By Indication
14.9.3. By Route of Administration
14.9.4. By Product Type
14.9.5. By Dosage Form
14.9.6. By Distribution Channel
14.9.7. By Country/Sub-region
15. Asia Pacific Ophthalmic Drugs Market Analysis and Forecast
15.1. Introduction
15.1.1. Key Findings
15.2. Market Value Forecast, by Therapeutic Class, 2017-2031
15.2.1. Anti-VEGF Agents
15.2.2. Anti-glaucoma Drugs
15.2.2.1. Alpha Agonist
15.2.2.2. Beta Blockers
15.2.2.3. Prostaglandin Analogs
15.2.2.4. Combined Medication
15.2.2.5. Others
15.2.3. Anti-inflammatory Drugs
15.2.3.1. Steroids
15.2.3.2. NSAIDs
15.2.4. Anti-infective Drugs
15.2.4.1. Anti-bacterial Drugs
15.2.4.2. Anti-fungal Drugs
15.2.4.3. Others
15.2.5. Anti-allergy Drugs
15.2.6. Others
15.3. Market Value Forecast, by Indication, 2017-2031
15.3.1. Dry Eye
15.3.2. Glaucoma
15.3.3. Infection/Inflammation
15.3.4. Retinal Disorders
15.3.4.1. Wet AMD
15.3.4.2. Dry AMD
15.3.4.3. Diabetic Retinopathy
15.3.4.4. Others
15.3.5. Allergy
15.3.6. Uveitis
15.3.7. Others
15.4. Market Value Forecast, by Route of Administration, 2017-2031
15.4.1. Topical
15.4.2. Local Ocular (intravitreal)
15.4.3. Others
15.5. Market Value Forecast, by Product Type, 2017-2031
15.5.1. Prescription
15.5.2. OTC
15.6. Market Value Forecast, by Dosage Form, 2017-2031
15.6.1. Eye Drops
15.6.2. Eye Solutions & Suspensions
15.6.3. Capsules & Tablets
15.6.4. Gels
15.6.5. Ointments
15.6.6. Others
15.7. Market Value Forecast, by Distribution Channel, 2017-2031
15.7.1. Hospital Pharmacies
15.7.2. Retail Pharmacies
15.7.3. Online Pharmacies
15.8. Market Value Forecast, by Country/Sub-region, 2017-2031
15.8.1. China
15.8.2. Japan
15.8.3. India
15.8.4. Australia & New Zealand
15.8.5. Rest of Asia Pacific
15.9. Market Attractiveness Analysis
15.9.1. By Therapeutic Class
15.9.2. By Indication
15.9.3. By Route of Administration
15.9.4. By Product Type
15.9.5. By Dosage Form
15.9.6. By Distribution Channel
15.9.7. By Country/Sub-region
16. Latin America Ophthalmic Drugs Market Analysis and Forecast
16.1. Introduction
16.1.1. Key Findings
16.2. Market Value Forecast, by Therapeutic Class, 2017-2031
16.2.1. Anti-VEGF Agents
16.2.2. Anti-glaucoma Drugs
16.2.2.1. Alpha Agonist
16.2.2.2. Beta Blockers
16.2.2.3. Prostaglandin Analogs
16.2.2.4. Combined Medication
16.2.2.5. Others
16.2.3. Anti-inflammatory Drugs
16.2.3.1. Steroids
16.2.3.2. NSAIDs
16.2.4. Anti-infective Drugs
16.2.4.1. Anti-bacterial Drugs
16.2.4.2. Anti-fungal Drugs
16.2.4.3. Others
16.2.5. Anti-allergy Drugs
16.2.6. Others
16.3. Market Value Forecast, by Indication, 2017-2031
16.3.1. Dry Eye
16.3.2. Glaucoma
16.3.3. Infection/Inflammation
16.3.4. Retinal Disorders
16.3.4.1. Wet AMD
16.3.4.2. Dry AMD
16.3.4.3. Diabetic Retinopathy
16.3.4.4. Others
16.3.5. Allergy
16.3.6. Uveitis
16.3.7. Others
16.4. Market Value Forecast, by Route of Administration, 2017-2031
16.4.1. Topical
16.4.2. Local Ocular (intravitreal)
16.4.3. Others
16.5. Market Value Forecast, by Product Type, 2017-2031
16.5.1. Prescription
16.5.2. OTC
16.6. Market Value Forecast, by Dosage Form, 2017-2031
16.6.1. Eye Drops
16.6.2. Eye Solutions & Suspensions
16.6.3. Capsules & Tablets
16.6.4. Gels
16.6.5. Ointments
16.6.6. Others
16.7. Market Value Forecast, by Distribution Channel, 2017-2031
16.7.1. Hospital Pharmacies
16.7.2. Retail Pharmacies
16.7.3. Online Pharmacies
16.8. Market Value Forecast, by Country/Sub-region,2017-2031
16.8.1. Brazil
16.8.2. Mexico
16.8.3. Rest of Latin America
16.9. Market Attractiveness Analysis
16.9.1. By Therapeutic Class
16.9.2. By Indication
16.9.3. By Route of Administration
16.9.4. By Product Type
16.9.5. By Dosage Form
16.9.6. By Distribution Channel
16.9.7. By Country/Sub-region
17. Middle East & Africa Ophthalmic Drugs Market Analysis and Forecast
17.1. Introduction
17.1.1. Key Findings
17.2. Market Value Forecast, by Therapeutic Class, 2017-2031
17.2.1. Anti-VEGF Agents
17.2.2. Anti-glaucoma Drugs
17.2.2.1. Alpha Agonist
17.2.2.2. Beta Blockers
17.2.2.3. Prostaglandin Analogs
17.2.2.4. Combined Medication
17.2.2.5. Others
17.2.3. Anti-inflammatory Drugs
17.2.3.1. Steroids
17.2.3.2. NSAIDs
17.2.4. Anti-infective Drugs
17.2.4.1. Anti-bacterial Drugs
17.2.4.2. Anti-fungal Drugs
17.2.4.3. Others
17.2.5. Anti-allergy Drugs
17.2.6. Others
17.3. Market Value Forecast, by Indication, 2017-2031
17.3.1. Dry Eye
17.3.2. Glaucoma
17.3.3. Infection/Inflammation
17.3.4. Retinal Disorders
17.3.4.1. Wet AMD
17.3.4.2. Dry AMD
17.3.4.3. Diabetic Retinopathy
17.3.4.4. Others
17.3.5. Allergy
17.3.6. Uveitis
17.3.7. Others
17.4. Market Value Forecast, by Route of Administration, 2017-2031
17.4.1. Topical
17.4.2. Local Ocular (intravitreal)
17.4.3. Others
17.5. Market Value Forecast, by Product Type, 2017-2031
17.5.1. Prescription
17.5.2. OTC
17.6. Market Value Forecast, by Dosage Form, 2017-2031
17.6.1. Eye Drops
17.6.2. Eye Solutions & Suspensions
17.6.3. Capsules & Tablets
17.6.4. Gels
17.6.5. Ointments
17.6.6. Others
17.7. Market Value Forecast, by Distribution Channel, 2017-2031
17.7.1. Hospital Pharmacies
17.7.2. Retail Pharmacies
17.7.3. Online Pharmacies
17.8. Market Value Forecast, by Country/Sub-region, 2017-2031
17.8.1. GCC Countries
17.8.2. South Africa
17.8.3. Rest of Middle East & Africa
17.9. Market Attractiveness Analysis
17.9.1. By Therapeutic Class
17.9.2. By Indication
17.9.3. By Route of Administration
17.9.4. By Product Type
17.9.5. By Dosage Form
17.9.6. By Distribution Channel
17.9.7. By Country/Sub-region
18. Competition Landscape
18.1. Market Player - Competition Matrix (by tier and size of companies)
18.2. Market Share Analysis, by Company, 2022
18.3. Company Profiles
18.3.1. AbbVie, Inc.
18.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
18.3.1.2. Product Portfolio
18.3.1.3. Financial Overview
18.3.1.4. SWOT Analysis
18.3.1.5. Strategic Overview
18.3.2. Alcon Vision LLC
18.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
18.3.2.2. Product Portfolio
18.3.2.3. Financial Overview
18.3.2.4. SWOT Analysis
18.3.2.5. Strategic Overview
18.3.3. Bausch Health Companies, Inc.
18.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
18.3.3.2. Product Portfolio
18.3.3.3. Financial Overview
18.3.3.4. SWOT Analysis
18.3.3.5. Strategic Overview
18.3.4. Bayer AG
18.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
18.3.4.2. Product Portfolio
18.3.4.3. Financial Overview
18.3.4.4. SWOT Analysis
18.3.4.5. Strategic Overview
18.3.5. Coherus BioSciences
18.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
18.3.5.2. Product Portfolio
18.3.5.3. Financial Overview
18.3.5.4. SWOT Analysis
18.3.5.5. Strategic Overview
18.3.6. F. Hoffmann-La Roche Ltd.
18.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
18.3.6.2. Product Portfolio
18.3.6.3. Financial Overview
18.3.6.4. SWOT Analysis
18.3.6.5. Strategic Overview
18.3.7. Novartis Pharmaceuticals Corporation
18.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
18.3.7.2. Product Portfolio
18.3.7.3. Financial Overview
18.3.7.4. SWOT Analysis
18.3.7.5. Strategic Overview
18.3.8. Pfizer, Inc.
18.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
18.3.8.2. Product Portfolio
18.3.8.3. Financial Overview
18.3.8.4. SWOT Analysis
18.3.8.5. Strategic Overview
18.3.9. Regeneron Pharmaceuticals, Inc.
18.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
18.3.9.2. Product Portfolio
18.3.9.3. Financial Overview
18.3.9.4. SWOT Analysis
18.3.9.5. Strategic Overview
18.3.10. Santen, Inc.
18.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)
18.3.10.2. Product Portfolio
18.3.10.3. Financial Overview
18.3.10.4. SWOT Analysis
18.3.10.5. Strategic Overview
18.3.11. Sun Pharmaceutical Industries Ltd.
18.3.11.1. Company Overview (HQ, Business Segments, Employee Strength)
18.3.11.2. Product Portfolio
18.3.11.3. Financial Overview
18.3.11.4. SWOT Analysis
18.3.11.5. Strategic Overview
18.3.12. Teva Pharmaceutical Industries Ltd.
18.3.12.1. Company Overview (HQ, Business Segments, Employee Strength)
18.3.12.2. Product Portfolio
18.3.12.3. Financial Overview
18.3.12.4. SWOT Analysis
18.3.12.5. Strategic Overview
List of Tables
Table 01: Global Ophthalmic Drugs Market Volume (Prescriptions in Mn) Forecast, by Dosage Form, 2017-2031
Table 02: Global Ophthalmic Drugs Market Value (US$ Mn) Forecast, by Therapeutic Class, 2017-2031
Table 03: Global Ophthalmic Drugs Market Value (US$ Mn) Forecast, by Anti-glaucoma Drugs, 2017-2031
Table 04: Global Ophthalmic Drugs Market Value (US$ Mn) Forecast, by Anti-inflammatory Drugs, 2017-2031
Table 05: Global Ophthalmic Drugs Market Value (US$ Mn) Forecast, by Anti-infective Drugs, 2017-2031
Table 06: Global Ophthalmic Drugs Market Value (US$ Mn) Forecast, by Indication, 2017-2031
Table 07: Global Ophthalmic Drugs Market Value (US$ Mn) Forecast, by Retinal Disorders, 2017-2031
Table 08: Global Ophthalmic Drugs Market Value (US$ Mn) Forecast, by Route of Administration, 2017-2031
Table 09: Global Ophthalmic Drugs Market Value (US$ Mn) Forecast, by Product Type, 2017‒2031
Table 10: Global Ophthalmic Drugs Market Value (US$ Mn) Forecast, by Dosage Form, 2017-2031
Table 11: Global Ophthalmic Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031
Table 12: Global Ophthalmic Drugs Market Value (US$ Mn) Forecast, by Region, 2017-2031
Table 13: North America Ophthalmic Drugs Market Value (US$ Mn) Forecast, by Country, 2017-2031
Table 14: North America Ophthalmic Drugs Market Value (US$ Mn) Forecast, by Therapeutic Class, 2017-2031
Table 15: North America Ophthalmic Drugs Market Value (US$ Mn) Forecast, by Anti-glaucoma Drugs, 2017-2031
Table 16: North America Ophthalmic Drugs Market Value (US$ Mn) Forecast, by Anti-inflammatory Drugs, 2017-2031
Table 17: North America Ophthalmic Drugs Market Value (US$ Mn) Forecast, by Anti-infective Drugs, 2017-2031
Table 18: North America Ophthalmic Drugs Market Value (US$ Mn) Forecast, by Indication, 2017-2031
Table 19: North America Ophthalmic Drugs Market Value (US$ Mn) Forecast, by Retinal Disorders, 2017-2031
Table 20: North America Ophthalmic Drugs Market Value (US$ Mn) Forecast, by Route of Administration, 2017-2031
Table 21: North America Ophthalmic Drugs Market Value (US$ Mn) Forecast, by Product Type, 2017‒2031
Table 22: North America Ophthalmic Drugs Market Value (US$ Mn) Forecast, by Dosage Form, 2017-2031
Table 23: North America Ophthalmic Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031
Table 24: Europe Ophthalmic Drugs Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
Table 25: Europe Ophthalmic Drugs Market Value (US$ Mn) Forecast, by Therapeutic Class, 2017-2031
Table 26: Europe Ophthalmic Drugs Market Value (US$ Mn) Forecast, by Anti-glaucoma Drugs, 2017-2031
Table 27: Europe Ophthalmic Drugs Market Value (US$ Mn) Forecast, by Anti-inflammatory Drugs, 2017-2031
Table 28: Europe Ophthalmic Drugs Market Value (US$ Mn) Forecast, by Anti-infective Drugs, 2017-2031
Table 29: Europe Ophthalmic Drugs Market Value (US$ Mn) Forecast, by Indication, 2017-2031
Table 30: Europe Ophthalmic Drugs Market Value (US$ Mn) Forecast, by Retinal Disorders, 2017-2031
Table 31: Europe Ophthalmic Drugs Market Value (US$ Mn) Forecast, by Route of Administration, 2017-2031
Table 32: Europe Ophthalmic Drugs Market Value (US$ Mn) Forecast, by Product Type, 2017‒2031
Table 33: Europe Ophthalmic Drugs Market Value (US$ Mn) Forecast, by Dosage Form, 2017-2031
Table 34: Europe Ophthalmic Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031
Table 35: Asia Pacific Ophthalmic Drugs Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
Table 36: Asia Pacific Ophthalmic Drugs Market Value (US$ Mn) Forecast, by Therapeutic Class, 2017-2031
Table 37: Asia Pacific Ophthalmic Drugs Market Value (US$ Mn) Forecast, by Anti-glaucoma Drugs, 2017-2031
Table 38: Asia Pacific Ophthalmic Drugs Market Value (US$ Mn) Forecast, by Anti-inflammatory Drugs, 2017-2031
Table 39: Asia Pacific Ophthalmic Drugs Market Value (US$ Mn) Forecast, by Anti-infective Drugs, 2017-2031
Table 40: Asia Pacific Ophthalmic Drugs Market Value (US$ Mn) Forecast, by Indication, 2017-2031
Table 41: Asia Pacific Ophthalmic Drugs Market Value (US$ Mn) Forecast, by Retinal Disorders, 2017-2031
Table 42: Asia Pacific Ophthalmic Drugs Market Value (US$ Mn) Forecast, by Route of Administration, 2017-2031
Table 43: Asia Pacific Ophthalmic Drugs Market Value (US$ Mn) Forecast, by Product Type, 2017‒2031
Table 44: Asia Pacific Ophthalmic Drugs Market Value (US$ Mn) Forecast, by Dosage Form, 2017-2031
Table 45: Asia Pacific Ophthalmic Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031
Table 46: Latin America Ophthalmic Drugs Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
Table 47: Latin America Ophthalmic Drugs Market Value (US$ Mn) Forecast, by Therapeutic Class, 2017-2031
Table 48: Latin America Ophthalmic Drugs Market Value (US$ Mn) Forecast, by Anti-glaucoma Drugs, 2017-2031
Table 49: Latin America Ophthalmic Drugs Market Value (US$ Mn) Forecast, by Anti-inflammatory Drugs, 2017-2031
Table 50: Latin America Ophthalmic Drugs Market Value (US$ Mn) Forecast, by Anti-infective Drugs, 2017-2031
Table 51: Latin America Ophthalmic Drugs Market Value (US$ Mn) Forecast, by Indication, 2017-2031
Table 52: Latin America Ophthalmic Drugs Market Value (US$ Mn) Forecast, by Retinal Disorders, 2017-2031
Table 53: Latin America Ophthalmic Drugs Market Value (US$ Mn) Forecast, by Route of Administration, 2017-2031
Table 54: Latin America Ophthalmic Drugs Market Value (US$ Mn) Forecast, by Product Type, 2017‒2031
Table 55: Latin America Ophthalmic Drugs Market Value (US$ Mn) Forecast, by Dosage Form, 2017-2031
Table 56: Latin America Ophthalmic Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031
Table 57: Middle East & Africa Ophthalmic Drugs Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
Table 58: Middle East & Africa Ophthalmic Drugs Market Value (US$ Mn) Forecast, by Therapeutic Class, 2017-2031
Table 59: Middle East & Africa Ophthalmic Drugs Market Value (US$ Mn) Forecast, by Anti-glaucoma Drugs, 2017-2031
Table 60: Middle East & Africa Ophthalmic Drugs Market Value (US$ Mn) Forecast, by Anti-inflammatory Drugs, 2017-2031
Table 61: Middle East & Africa Ophthalmic Drugs Market Value (US$ Mn) Forecast, by Anti-infective Drugs, 2017-2031
Table 62: Middle East & Africa Ophthalmic Drugs Market Value (US$ Mn) Forecast, by Indication, 2017-2031
Table 63: Middle East & Africa Ophthalmic Drugs Market Value (US$ Mn) Forecast, by Retinal Disorders, 2017-2031
Table 64: Middle East & Africa Ophthalmic Drugs Market Value (US$ Mn) Forecast, by Route of Administration, 2017-2031
Table 65: Middle East & Africa Ophthalmic Drugs Market Value (US$ Mn) Forecast, by Product Type, 2017‒2031
Table 66: Middle East & Africa Ophthalmic Drugs Market Value (US$ Mn) Forecast, by Dosage Form, 2017-2031
Table 67: Middle East & Africa Ophthalmic Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031
List of Figures
Figure 01: Global Ophthalmic Drugs Market Value Share Analysis, by Therapeutic Class 2022 and 2031
Figure 02: Global Ophthalmic Drugs Market Attractiveness Analysis, Therapeutic Class, 2023-2031
Figure 03: Global Ophthalmic Drugs Market Revenue (US$ Mn), by Anti-VEGF Agents, 2017-2031
Figure 04: Global Ophthalmic Drugs Market Revenue (US$ Mn), by Anti-glaucoma Drugs, 2017-2031
Figure 05: Global Ophthalmic Drugs Market Revenue (US$ Mn), by Anti-inflammatory Drugs, 2017-2031
Figure 06: Global Ophthalmic Drugs Market Revenue (US$ Mn), by Anti-infective Drugs, 2017-2031
Figure 07: Global Ophthalmic Drugs Market Revenue (US$ Mn), by Anti-allergy Drugs, 2017-2031
Figure 08: Global Ophthalmic Drugs Market Revenue (US$ Mn), by Others, 2017-2031
Figure 09: Global Ophthalmic Drugs Market Value Share Analysis, by Indication, 2022 and 2031
Figure 10: Global Ophthalmic Drugs Market Attractiveness Analysis, Indication, 2023-2031
Figure 11: Global Ophthalmic Drugs Market Revenue (US$ Mn), by Dry Eye, 2017-2031
Figure 12: Global Ophthalmic Drugs Market Revenue (US$ Mn), by Glaucoma, 2017-2031
Figure 13: Global Ophthalmic Drugs Market Revenue (US$ Mn), by Infection/Inflammation, 2017-2031
Figure 14: Global Ophthalmic Drugs Market Revenue (US$ Mn), by Retinal Disorders, 2017-2031
Figure 15: Global Ophthalmic Drugs Market Revenue (US$ Mn), by Allergy, 2017-2031
Figure 16: Global Ophthalmic Drugs Market Revenue (US$ Mn), by Uveitis 2017-2031
Figure 17: Global Ophthalmic Drugs Market Revenue (US$ Mn), by Others, 2017-2031
Figure 18: Global Ophthalmic Drugs Market Value Share Analysis, by Route of Administration, 2022 and 2031
Figure 19: Global Ophthalmic Drugs Market Attractiveness Analysis, by Route of Administration, 2023-2031
Figure 20: Global Ophthalmic Drugs Market Revenue (US$ Mn), by Topical, 2017-2031
Figure 21: Global Ophthalmic Drugs Market Revenue (US$ Mn), by Local Ocular (intravitreal), 2017-2031
Figure 22: Global Ophthalmic Drugs Market Revenue (US$ Mn), by Others, 2017-2031
Figure 23: Global Ophthalmic Drugs Market Value Share Analysis, by Product Type, 2022 and 2031
Figure 24: Global Ophthalmic Drugs Market Attractiveness Analysis, by Product Type, 2023-2031
Figure 25: Global Ophthalmic Drugs Market Value (US$ Mn), by Prescription, 2017‒2031
Figure 26: Global Ophthalmic Drugs Market Value (US$ Mn), by OTC, 2017‒2031
Figure 27: Global Ophthalmic Drugs Market Value Share Analysis, by Dosage Form, 2022 and 2031
Figure 28: Global Ophthalmic Drugs Market Attractiveness Analysis, Dosage Form, 2023-2031
Figure 29: Global Ophthalmic Drugs Market Revenue (US$ Mn), by Eye Drops, 2017-2031
Figure 30: Global Ophthalmic Drugs Market Revenue (US$ Mn), by Eye Solutions & Suspensions, 2017-2031
Figure 31: Global Ophthalmic Drugs Market Revenue (US$ Mn), by Capsules & Tablets, 2017-2031
Figure 32: Global Ophthalmic Drugs Market Revenue (US$ Mn), by Gels, 2017-2031
Figure 33: Global Ophthalmic Drugs Market Revenue (US$ Mn), by Ointments, 2017-2031
Figure 34: Global Ophthalmic Drugs Market Revenue (US$ Mn), by Others, 2017-2031
Figure 35: Global Ophthalmic Drugs Market Value Share Analysis, by Distribution Channel, 2022 and 2031
Figure 36: Global Ophthalmic Drugs Market Attractiveness Analysis, by Distribution Channel, 2023-2031
Figure 37: Global Ophthalmic Drugs Market Revenue (US$ Mn), by Hospital Pharmacies, 2017-2031
Figure 38: Global Ophthalmic Drugs Market Revenue (US$ Mn), by Retail Pharmacies, 2017-2031
Figure 39: Global Ophthalmic Drugs Market Revenue (US$ Mn), by Online Pharmacies, 2017-2031
Figure 40: Global Ophthalmic Drugs Market Value Share Analysis, by Region, 2022 and 2031
Figure 41: Global Ophthalmic Drugs Market Attractiveness Analysis, by Region, 2023-2031
Figure 42: North America Ophthalmic Drugs Market Value (US$ Mn) Forecast, 2017-2031
Figure 43: North America Ophthalmic Drugs Market Value Share Analysis, by Country, 2022 and 2031
Figure 44: North America Ophthalmic Drugs Market Attractiveness Analysis, by Country, 2023-2031
Figure 45: North America Ophthalmic Drugs Market Value Share Analysis, by Therapeutic Class 2022 and 2031
Figure 46: North America Ophthalmic Drugs Market Attractiveness Analysis, Therapeutic Class, 2023-2031
Figure 47: North America Ophthalmic Drugs Market Value Share Analysis, by Indication, 2022 and 2031
Figure 48: North America Ophthalmic Drugs Market Attractiveness Analysis, Indication, 2023-2031
Figure 49: North America Ophthalmic Drugs Market Value Share Analysis, by Route of Administration, 2022 and 2031
Figure 50: North America Ophthalmic Drugs Market Attractiveness Analysis, by Route of Administration, 2023-2031
Figure 51: North America Ophthalmic Drugs Market Value Share Analysis, by Product Type, 2022 and 2031
Figure 52: North America Ophthalmic Drugs Market Attractiveness Analysis, by Product Type, 2023-2031
Figure 53: North America Ophthalmic Drugs Market Value Share Analysis, by Dosage Form, 2022 and 2031
Figure 54: North America Ophthalmic Drugs Market Attractiveness Analysis, Dosage Form, 2023-2031
Figure 55: North America Ophthalmic Drugs Market Value Share Analysis, by Distribution Channel, 2022 and 2031
Figure 56: North America Ophthalmic Drugs Market Attractiveness Analysis, by Distribution Channel, 2023-2031
Figure 57: Europe Ophthalmic Drugs Market Value (US$ Mn) Forecast, 2017-2031
Figure 58: Europe Ophthalmic Drugs Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
Figure 59: Europe Ophthalmic Drugs Market Attractiveness Analysis, by Country/Sub-region, 2023-2031
Figure 60: Europe Ophthalmic Drugs Market Value Share Analysis, by Therapeutic Class, 2022 and 2031
Figure 61: Europe Ophthalmic Drugs Market Attractiveness Analysis, Therapeutic Class, 2023-2031
Figure 62: Europe Ophthalmic Drugs Market Value Share Analysis, by Indication, 2022 and 2031
Figure 63: Europe Ophthalmic Drugs Market Attractiveness Analysis, Indication, 2023-2031
Figure 64: Europe Ophthalmic Drugs Market Value Share Analysis, by Route of Administration, 2022 and 2031
Figure 65: Europe Ophthalmic Drugs Market Attractiveness Analysis, by Route of Administration, 2023-2031
Figure 66: Europe Ophthalmic Drugs Market Value Share Analysis, by Product Type, 2022 and 2031
Figure 67: Europe Ophthalmic Drugs Market Attractiveness Analysis, by Product Type, 2023-2031
Figure 68: Europe Ophthalmic Drugs Market Value Share Analysis, by Dosage Form, 2022 and 2031
Figure 69: Europe Ophthalmic Drugs Market Attractiveness Analysis, Dosage Form, 2023-2031
Figure 70: Europe Ophthalmic Drugs Market Value Share Analysis, by Distribution Channel, 2022 and 2031
Figure 71: Europe Ophthalmic Drugs Market Attractiveness Analysis, by Distribution Channel, 2023-2031
Figure 72: Asia Pacific Ophthalmic Drugs Market Value (US$ Mn) Forecast, 2017-2031
Figure 73: Asia Pacific Ophthalmic Drugs Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
Figure 74: Asia Pacific Ophthalmic Drugs Market Attractiveness Analysis, by Country/Sub-region, 2023-2031
Figure 75: Asia Pacific Ophthalmic Drugs Market Value Share Analysis, by Therapeutic Class, 2022 and 2031
Figure 76: Asia Pacific Ophthalmic Drugs Market Attractiveness Analysis, Therapeutic Class, 2023-2031
Figure 77: Asia Pacific Ophthalmic Drugs Market Value Share Analysis, by Indication, 2022 and 2031
Figure 78: Asia Pacific Ophthalmic Drugs Market Attractiveness Analysis, Indication, 2023-2031
Figure 79: Asia Pacific Ophthalmic Drugs Market Value Share Analysis, by Route of Administration, 2022 and 2031
Figure 80: Asia Pacific Ophthalmic Drugs Market Attractiveness Analysis, by Route of Administration, 2023-2031
Figure 81: Asia Pacific Ophthalmic Drugs Market Value Share Analysis, by Product Type, 2022 and 2031
Figure 82: Asia Pacific Ophthalmic Drugs Market Attractiveness Analysis, by Product Type, 2023-2031
Figure 83: Asia Pacific Ophthalmic Drugs Market Value Share Analysis, by Dosage Form, 2022 and 2031
Figure 84: Asia Pacific Ophthalmic Drugs Market Attractiveness Analysis, Dosage Form, 2023-2031
Figure 85: Asia Pacific Ophthalmic Drugs Market Value Share Analysis, by Distribution Channel, 2022 and 2031
Figure 86: Asia Pacific Ophthalmic Drugs Market Attractiveness Analysis, by Distribution Channel, 2023-2031
Figure 87: Latin America Ophthalmic Drugs Market Value (US$ Mn) Forecast, 2017-2031
Figure 88: Latin America Ophthalmic Drugs Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
Figure 89: Latin America Ophthalmic Drugs Market Attractiveness Analysis, by Country/Sub-region, 2023-2031
Figure 90: Latin America Ophthalmic Drugs Market Value Share Analysis, by Therapeutic Class, 2022 and 2031
Figure 91: Latin America Ophthalmic Drugs Market Attractiveness Analysis, Therapeutic Class, 2023-2031
Figure 92: Latin America Ophthalmic Drugs Market Value Share Analysis, by Indication, 2022 and 2031
Figure 93: Latin America Ophthalmic Drugs Market Attractiveness Analysis, Indication, 2023-2031
Figure 94: Latin America Ophthalmic Drugs Market Value Share Analysis, by Route of Administration, 2022 and 2031
Figure 95: Latin America Ophthalmic Drugs Market Attractiveness Analysis, by Route of Administration, 2023-2031
Figure 96: Latin America Ophthalmic Drugs Market Value Share Analysis, by Product Type, 2022 and 2031
Figure 97: Latin America Ophthalmic Drugs Market Attractiveness Analysis, by Product Type, 2023-2031
Figure 98: Latin America Ophthalmic Drugs Market Value Share Analysis, by Dosage Form, 2022 and 2031
Figure 99: Latin America Ophthalmic Drugs Market Attractiveness Analysis, Dosage Form, 2023-2031
Figure 100: Latin America Ophthalmic Drugs Market Value Share Analysis, by Distribution Channel, 2022 and 2031
Figure 101: Latin America Ophthalmic Drugs Market Attractiveness Analysis, by Distribution Channel, 2023-2031
Figure 102: Middle East & Africa Ophthalmic Drugs Market Value (US$ Mn) Forecast, 2017-2031
Figure 103: Middle East & Africa Ophthalmic Drugs Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
Figure 104: Middle East & Africa Ophthalmic Drugs Market Attractiveness Analysis, by Country/Sub-region, 2023-2031
Figure 105: Middle East & Africa Ophthalmic Drugs Market Value Share Analysis, by Therapeutic Class 2022 and 2031
Figure 106: Middle East & Africa Ophthalmic Drugs Market Attractiveness Analysis, Therapeutic Class, 2023-2031
Figure 107: Middle East & Africa Ophthalmic Drugs Market Value Share Analysis, by Indication, 2022 and 2031
Figure 108: Middle East & Africa Ophthalmic Drugs Market Attractiveness Analysis, Indication, 2023-2031
Figure 109: Middle East & Africa Ophthalmic Drugs Market Value Share Analysis, by Route of Administration, 2022 and 2031
Figure 110: Middle East & Africa Ophthalmic Drugs Market Attractiveness Analysis, by Route of Administration, 2023-2031
Figure 111: Middle East & Africa Ophthalmic Drugs Market Value Share Analysis, by Product Type, 2022 and 2031
Figure 112: Middle East & Africa Ophthalmic Drugs Market Attractiveness Analysis, by Product Type, 2023-2031
Figure 113: Middle East & Africa Ophthalmic Drugs Market Value Share Analysis, by Dosage Form, 2022 and 2031
Figure 114: Middle East & Africa Ophthalmic Drugs Market Attractiveness Analysis, Dosage Form, 2023-2031
Figure 115: Middle East & Africa Ophthalmic Drugs Market Value Share Analysis, by Distribution Channel, 2022 and 2031
Figure 116: Middle East & Africa Ophthalmic Drugs Market Attractiveness Analysis, by Distribution Channel, 2023-2031